SRRK Stock Forecast & Price Target

Scholar Rock Holding Corp has demonstrated a positive outlook in the biopharmaceutical sector, particularly in its focus on innovative treatments for serious diseases driven by protein growth factors, including Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. Recent market responses indicate increased physician confidence regarding the chronic use of their therapies, highlighted by a ~4% rise in SRRK shares, reflecting optimism in the efficacy and safety of their treatments. Furthermore, feedback from key opinion leaders emphasizes the durable benefits and functional improvements associated with apitegromab, supporting expectations for proactive market uptake upon launch, thereby enhancing the company’s growth prospects.

Scholar Rock Holding Corp's stock faces a negative outlook primarily due to the significant delays in the commercial launch of its lead product, apitegromab, which has now been pushed back to 2026 in the US and 2026 in the EU, affecting peak sales estimates significantly to $1.7 billion by 2035. The issuance of a Complete Response Letter (CRL) indicates regulatory setbacks, which not only delays approval but also increases competitive risks as other market players may establish new standards of care in the interim. Furthermore, despite some expert opinions downplaying the importance of the CRL, the ongoing uncertainties related to regulatory approval and market positioning could further weaken investor confidence and negate potential financial gains for the company.